UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.)

File Che	 □ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) □ Definitive Proxy Statement □ Definitive Additional Materials 					
	Diffusio ₂ n					
	Pharmaceuticals Inc.					
	Diffusion Pharmaceuticals Inc.					
	(Name of Registrant as Specified In Its Charter)					
	Not Applicable					
	(Name of Person(s) Filing Proxy Statement, if other than the Registrant)					
\boxtimes	ment of Filing Fee (Check the appropriate box): No fee required. Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.					
	(1) Title of each class of securities to which transaction applies:					
	 (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: 					
	(5) Total fee paid:					
□ Fee paid previously with preliminary materials. □ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.						
	(1) Amount Previously Paid:					
	(2) Form, Schedule or Registration Statement No.: (3) Filing Party:					
	(4) Date Filed:					



		Your vote matters – here's how to vote! You may vote online or by phone instead of mailing this card. Online Go to www.envisionreports.com/DFFN or scan the QR code – login details are located in the shaded bar below.		
		·	Phone Call toll free 1-800-652-V the USA, US territories a	
Using a <u>black ink</u> pen, mark your votes with an X as shown Please do not write outside the designated areas.	in this example.		Save paper, time and Sign up for electroni www.envisionreports	c delivery at
2021 Annual Meeting of Stock	holders Proxy Card	X X		
▼ IF V	OTING BY MAIL, SIGN, DETACH AND RETURN TH	IE BOTTOM PORTION IN THE ENCLOSI	ED ENVELOPE. ▼	
Proposals — The Board of Directors re EVERY 1 YEAR with respect to Propos	commend a vote \underline{FOR} all the nomine at 4.	es listed, <u>FOR</u> Proposals 2 a	and 3, and for a frequency	of _L
1. Election of Directors:				— т
OI - Robert Adams	hhold 02 - Robert J. Cobuzzi, Jr., Ph.D.	For Withhold 03 - Er	ic Francois	or Withhold
C4 - Mark T. Giles	05 - Jane H. Hollingsworth	06 - Di	iana Lanchoney, M.D.	
07 - Alan Levin]			
To ratify the selection of KPMG LLP as our indeper registered public accounting firm for the year end December 31, 2021.		To approve, on an advisory basis, executive officers during the yea disclosed in the accompanying pr	r ended December 31, 2020, as	For Against Abstain
 To approve, on an advisory basis, the frequency of future advisory votes on the compensation of our named executed officers. 	1 Year 2 Years 3 Years Abstain			
B Authorized Signatures — This section	must be completed for your vote to	count. Please date and sign	below.	
Please sign exactly as name(s) appears hereon. Joir full title.	t owners should each sign. When signing as	attorney, executor, administrator,	corporate officer, trustee, guard	ian, or custodian, please give
Date (mm/dd/yyyy) — Please print date below.	Signature 1 – Please ke ep s	ignature within the box.	Signature 2 — Please keep sign	ature within the box.
/ /				
, ,	100		<u> </u>	
	1 U P X			+

The 2021 Annual Meeting of Stockholders of Diffusion Pharmaceuticals Inc. will be held on June 25, 2021 at 1 p.m. Eastern Time virtually via the internet at www.meetingcenter.io/204775050.

To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form.

The password for this meeting is - DFFN2021.

Important notice regarding the Internet availability of proxy materials for the 2021 Annual Meeting of Stockholders.

The material is available at: www.envisionreports.com/DFFN



Small steps make an impact.

Help the environment by consenting to receive electronic delivery, sign up at www.envisionreports.com/DFFN



▼ IF VOTING BY MAIL, SIGN, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. ▼

Diffusion Pharmaceuticals Inc.



Notice of 2021 Annual Meeting of Stockholders

Proxy Solicited by Board of Directors for Annual Meeting – June 25, 2021

Robert J. Cobuzzi, Jr, Ph.D., William K. Hornung, and William R. Elder, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the signatory hereof, with all the powers which such signatory would possess if personally present, at the Annual Meeting of Stockholders of Diffusion Pharmaceuticals Inc. to be held on June 25, 2021 or at any postponement or adjournment thereof.

Shares represented by this proxy will be voted in the manner directed herein by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR the election of each of the Board of Directors' nominees in Proposal 1, FOR Proposals 2 and 3, and for a frequency of EVERY 1 YEAR with respect to Proposal 4.

In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the meeting.

(Items to be voted appear on reverse side)

C Non-Voting Items			
Change of Address — Please print new address below.	Comments - Please print your comments below.		